Occudo Quantitative Strategies LP Invests $648,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Occudo Quantitative Strategies LP bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 6,132 shares of the medical equipment provider’s stock, valued at approximately $648,000.

Several other institutional investors also recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp lifted its position in Zimmer Biomet by 19.9% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 8,684 shares of the medical equipment provider’s stock valued at $917,000 after purchasing an additional 1,443 shares during the last quarter. Meridiem Capital Partners LP bought a new position in Zimmer Biomet during the fourth quarter valued at $11,506,000. Moore Capital Management LP bought a new position in Zimmer Biomet during the fourth quarter valued at $4,977,000. Lighthouse Investment Partners LLC bought a new position in Zimmer Biomet during the fourth quarter valued at $2,007,000. Finally, Jefferies Financial Group Inc. lifted its position in Zimmer Biomet by 28.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 18,680 shares of the medical equipment provider’s stock valued at $1,973,000 after purchasing an additional 4,133 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ZBH. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Robert W. Baird lowered their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. Finally, Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $113.45.

Zimmer Biomet Stock Down 2.3%

NYSE:ZBH opened at $95.23 on Thursday. The company has a market cap of $18.84 billion, a PE ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $122.17. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $103.89 and its two-hundred day moving average is $105.97.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. Zimmer Biomet’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.94 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.